

# Oncology Brief from ASCO 2015: Update on Kidney Cancer and Prostate Cancer

Anil Kapoor, MD, FRCSC

Professor of Surgery (Urology), McMaster University, Associate Editor (Oncology), Canadian Urological Association Journal (CUAJ), Hamilton, ON

Cite as: *Can Urol Assoc J* 2015;9(7-8Suppl4):S157. <http://dx.doi.org/10.5489/cuaj.3211>  
Published online August 10, 2015.

The 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) included a wealth of new research across a wide spectrum of different malignancies. In total, almost 5000 abstracts were accepted for inclusion in the event's program.

ASCO 2015 continued the long Chicago tradition of an annual tsunami of oncology research information that many find overwhelming; in this report the *CUAJ* has attempted to synthesize the key research in prostate cancer and kidney cancer for our readership. We have summarized the *Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer (STAMPEDE)* and *Phase III Randomized Study of Adjuvant Radiotherapy With Versus Without Concurrent*

*Goserelin in Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer (GETUG)* trials providing further evidence of the benefit of early docetaxel added to hormone therapy in advanced prostate cancer. Also included is a recap of the latest data on radium-223 in castrate-resistant prostate cancer (CRPC), the agent most recent approved to fight advanced prostate cancer. In the kidney cancer domain, we summarize the latest data on the checkpoint inhibitors, sequencing TKI and mTORi, and efficacy in non-clear cell histology. We hope you find this report informative and useful for your summer reading pleasure!

**Competing interests:** Dr. Kapoor is a member of the Speakers Bureau for Pfizer and Novartis. He has also received grants from Pfizer, GSK, Novartis, and Amgen. He is currently participating in a clinical trial with NCIC, Pfizer, GSK, Novartis, and Amgen.

**Correspondence:** Dr. Anil Kapoor, McMaster Institute of Urology, St. Joseph's Healthcare, Hamilton, ON; [akapoor@mcmaster.ca](mailto:akapoor@mcmaster.ca)